{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:54:16Z","timestamp":1791161656179,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001155","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,1,23]],"date-time":"2008-01-23T00:00:00Z","timestamp":1201046400000}}],"reference-count":122,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001155.pub2","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T01:11:33Z","timestamp":1202260293000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":158,"title":["Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women"],"prefix":"10.1002","author":[{"given":"George A","family":"Wells","sequence":"first","affiliation":[{"name":"University of Ottawa; Department of Epidemiology and Community Medicine; Room H1-1 40 Ruskin Street Ottawa Ontario Canada K1Y 4W7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Cranney","sequence":"additional","affiliation":[{"name":"Ottawa Hospital; Division of Rheumatology; 1053 Carling Ave Ottawa Ontario Canada K1Y 4E9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Peterson","sequence":"additional","affiliation":[{"name":"Ottawa Civic Hospital \/ Loeb Research Institute; Clinical Epidemiology Unit; 1053 Carling Avenue Ottawa Ontario Canada K1Y 4E9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boucher","sequence":"additional","affiliation":[{"name":"HTA Development Canadian Agency for Drugs and Technologies in Health (CADTH); 865 Carling Ave Suite 600 Ottawa Ontario Canada K1S 5S8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[{"name":"University of Ottawa; CIET, Institute of Population Health; 1 Stewart St. Room 312 Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Welch","sequence":"additional","affiliation":[{"name":"University of Ottawa; Centre for Global Health, Institute of Population Health; 1 Stewart Street, Room 206 Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Coyle","sequence":"additional","affiliation":[{"name":"Ottawa Health Research Institute; Epidemiology and Community Medicine; 451 Smyth Rd. Ottawa Ontario Canada K1H 8M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"University of Ottawa; Department of Medicine; 1 Stewart Street Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD001155.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans","year":"2003","journal-title":"Archives of Internal Medicine"},{"issue":"9041","key":"10.1002\/14651858.CD001155.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.[see comment]","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub2-BIB0003|cit3","first-page":"265","article-title":"Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers","volume":"82","author":"Bone","year":"1997","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"American Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD001155.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. [see comment]","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1742-1241.2001.tb11111.x","article-title":"Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis","volume":"55","author":"Dursun","year":"2001","journal-title":"International Journal of Clinical Practice"},{"issue":"9","key":"10.1002\/14651858.CD001155.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"Journal of Bone and Mineral Research"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.4065\/77.10.1044","article-title":"Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. [see comment]","volume":"77","author":"Greenspan","year":"2002","journal-title":"Mayo Clinic Proceedings"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1002\/14651858.CD001155.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. [see comment]","volume":"333","author":"Liberman","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1007\/BF01623004","article-title":"Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin","volume":"3 Suppl 3","author":"Adami","year":"1993","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","article-title":"Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"17","author":"Adami","year":"1995","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/BMR-2004-17106","article-title":"Effect of alendronate on bone density and bone markers in postmenopausal osteoporosis","volume":"17","author":"Aki","year":"2003","journal-title":"Journal of Back & Musculoskeletal Rehabilitation"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1210\/jcem.87.6.8575","article-title":"Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women","volume":"87","author":"Bell","year":"2002","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"50","key":"10.1002\/14651858.CD001155.pub2-BIB0016|cit16","first-page":"2799","article-title":"[The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungarian of an international multicenter clinical study)]","volume":"140","author":"Bettembuk","year":"1999","journal-title":"Orvosi Hetilap"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. [erratum appears in J Clin Endocrinol Metab 2001 Feb;86(2):938]","volume":"85","author":"Black","year":"2000","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"13","key":"10.1002\/14651858.CD001155.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. [see comment]","volume":"349","author":"Black","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone (1-34)) with alendronate in postmenopausal women with osteoporosis. [see comment]","volume":"87","author":"Body","year":"2002","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub2-BIB0021|cit21","first-page":"720","article-title":"Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate\/Estrogen Study Group","volume":"85","author":"Bone","year":"2000","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD001155.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women. [see comment]","volume":"350","author":"Bone","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"5S","key":"10.1002\/14651858.CD001155.pub2-BIB0023|cit23","first-page":"S476","article-title":"Alendronate vs calcium for treatment of osteoporosis in postmenopausal women.","volume":"350","author":"Bonnick","year":"1998","journal-title":"Bone"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s001980050261","article-title":"Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women","volume":"10","author":"Bouxsein","year":"1999","journal-title":"Osteoporosis International"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00774-003-0438-2","article-title":"Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis","volume":"21","author":"Chailurkit","year":"2003","journal-title":"Journal of Bone & Mineral Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1081\/ERC-120028385","article-title":"Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis","volume":"30","author":"Chailurkit","year":"2004","journal-title":"Endocrine Research"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub2-BIB0028|cit28","first-page":"306","article-title":"[The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis]. [Chinese]","volume":"24","author":"Cheng","year":"2002","journal-title":"Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001155.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/BF01623003","article-title":"Short term effect of alendronate on bone mass and bone remodeling in postmenopausal women","volume":"3","author":"Chesnut","year":"1993","journal-title":"Osteoporosis International"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.283.10.1318","article-title":"Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group","volume":"283","author":"Cummings","year":"2000","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0015-0282(03)00757-X","article-title":"Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women","volume":"80","author":"Davas","year":"2003","journal-title":"Fertility & Sterility"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/8756-3282(95)00436-X","article-title":"Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. [erratum appears in Bone 1996 Jul;19(1):78]","volume":"18","author":"Devogelaer","year":"1996","journal-title":"Bone"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0034|cit34","first-page":"1783","article-title":"Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women","volume":"85","author":"Downs","year":"2000","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1210\/jc.2003-030198","article-title":"Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis","volume":"89","author":"Evio","year":"2004","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s001980200048","article-title":"Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study","volume":"13","author":"Gonnelli","year":"2002","journal-title":"Osteoporosis International"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. [summary for patients in Ann Intern Med. 2002 Dec 3;137(11):I31; PMID: 12459003]","volume":"137","author":"Greenspan","year":"2002","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"742","DOI":"10.7326\/0003-4819-136-10-200205210-00009","article-title":"Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. [summary for patients in Ann Intern Med. 2002 May 21;136(10):I54; PMID: 12020160]","volume":"136","author":"Greenspan","year":"2002","journal-title":"Annals of Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD001155.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.289.19.2525","article-title":"Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial","volume":"289","author":"Greenspan","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub2-BIB0040|cit40","first-page":"1399","article-title":"The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women","volume":"76","author":"Harris","year":"1993","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub2-BIB0041|cit41","first-page":"315","article-title":"Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. [see comment]","volume":"60","author":"Heijckmann","year":"2002","journal-title":"Netherlands Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD001155.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1345\/aph.1E580","article-title":"Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women","volume":"39","author":"Ho","year":"2005","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis & Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Current Medical Research & Opinion"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3349\/ymj.2004.45.4.676","article-title":"Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis","volume":"45","author":"Iwamoto","year":"2004","journal-title":"Yonsei Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. [see comment]","volume":"87","author":"Johnell","year":"2002","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s0022330001142","article-title":"The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study","volume":"67","author":"Kung","year":"2000","journal-title":"Calcified Tissue International"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00774-004-0508-0","article-title":"Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study","volume":"22","author":"Kushida","year":"2004","journal-title":"Journal of Bone & Mineral Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S8756-3282(00)00378-1","article-title":"Alendronate prevents bone loss in Chinese women with osteoporosis","volume":"27","author":"Lau","year":"2000","journal-title":"Bone"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.GME.0000119981.77837.1F","article-title":"Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis","volume":"11","author":"Luckey","year":"2004","journal-title":"Menopause"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub2-BIB0051|cit51","first-page":"51","article-title":"Calcitriol and alendronate combination treatment in menopausal women with low bone mass","volume":"21","author":"Malavolta","year":"1999","journal-title":"International Journal of Tissue Reactions"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-128-4-199802150-00001","article-title":"Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. [see comment]","volume":"128","author":"McClung","year":"1998","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1210\/jc.2003-031672","article-title":"Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study","volume":"89","author":"McClung","year":"2004","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub2-BIB0054|cit54","first-page":"1116","article-title":"Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women","volume":"86","author":"Murphy","year":"2001","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1359\/JBMR.050403","article-title":"Serum TRACP 5b is a useful marker for monitoring alendronate treatment: Comparison with other markers of bone turnover","volume":"20","author":"Nenonen","year":"2005","journal-title":"Journal of Bone & Mineral Research"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/jcem.87.4.8323","article-title":"Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis","volume":"87","author":"Palomba","year":"2002","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub2-BIB0057|cit57","first-page":"689","article-title":"[Effect of alendronate therapy on bone turnover--results of a multicenter study]. [Slovak]","volume":"46","author":"Payer","year":"2000","journal-title":"Vnitrni Lekarstvi"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group","volume":"24","author":"Ravn","year":"1999","journal-title":"Bone"},{"issue":"7","key":"10.1002\/14651858.CD001155.pub2-BIB0059|cit59","first-page":"2363","article-title":"Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study","volume":"84","author":"Ravn","year":"1999","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD001155.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","article-title":"Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. [see comment]","volume":"131","author":"Ravn","year":"1999","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub2-BIB0061|cit61","first-page":"1492","article-title":"Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group","volume":"85","author":"Ravn","year":"2000","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD001155.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00198-006-0200-4","article-title":"Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study","volume":"17","author":"Rhee","year":"2006","journal-title":"Osteoporosis International"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub2-BIB0063|cit63","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. [see comment]","volume":"85","author":"Rittmaster","year":"2000","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"Journal of Bone & Mineral Research"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jbmr.5650091121","article-title":"Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis","volume":"9","author":"Rossini","year":"1994","journal-title":"Journal of Bone & Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S8756-3282(00)00291-X","article-title":"Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis","volume":"27","author":"Rossini","year":"2000","journal-title":"Bone"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub2-BIB0067|cit67","first-page":"309","article-title":"The effect of alendronate in the treatment of postmenopausal osteoporosis","volume":"104","author":"Rozkydal","year":"2003","journal-title":"Bratislavske Lekarske Listy"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s001980070035","article-title":"A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial","volume":"11","author":"Sahota","year":"2000","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2796.2004.01317.x","article-title":"Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International","volume":"255","author":"Sambrook","year":"2004","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00198-003-1571-4","article-title":"Alendronate in the prevention of osteoporosis: 7-year follow-up","volume":"15","author":"Sambrook","year":"2004","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1385\/JCD:6:4:315","article-title":"What predicts early fracture or bone loss on bisphosphonate therapy?","volume":"6","author":"Sawka","year":"2003","journal-title":"Journal of Clinical Densitometry"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1359\/jbmr.1999.14.8.1387","article-title":"Alendronate increases bone density and bone strength at the distal radius in postmenopausal women","volume":"14","author":"Schneider","year":"1999","journal-title":"Journal of Bone & Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging-Clinical & Experimental Research"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0074|cit74","first-page":"40","article-title":"The antifracture efficacy of alendronate","volume":"Supplement. 101","author":"Seeman","year":"1999","journal-title":"International Journal of Clinical Practice"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","article-title":"Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study","volume":"24","author":"Simon","year":"2002","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1385\/JCD:5:1:027","article-title":"Effect of two forms of alendronate administration upon bone mass after two years of treatment","volume":"5","author":"Sosa","year":"2002","journal-title":"Journal of Clinical Densitometry"},{"issue":"1-2","key":"10.1002\/14651858.CD001155.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0009-8981(99)00151-5","article-title":"Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis","volume":"288","author":"Stepan","year":"1999","journal-title":"Clinica Chimica Acta"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/humrep\/15.10.2087","article-title":"Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study","volume":"15","author":"Tiras","year":"2000","journal-title":"Human Reproduction"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","article-title":"Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis","volume":"101","author":"Tucci","year":"1996","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0080|cit80","unstructured":"Tutuncu L Arslanhan N Mungen E Yilmaz S Yergok YZ Combined usage of raloxifene and alendronate: Effects on biochemical markers. [Turkish] Nobel Medicus 2005 519"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S8756-3282(03)00082-6","article-title":"Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial","volume":"33","author":"Uusi-Rasi","year":"2003","journal-title":"Bone"},{"issue":"3","key":"10.1002\/14651858.CD001155.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1359\/jbmr.2000.15.3.586","article-title":"The effect of alendronate on bone mass after distal forearm fracture","volume":"15","author":"Poest","year":"2000","journal-title":"Journal of Bone & Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/8756-3282(95)00400-9","article-title":"Sustained response to intravenous alendronate in postmenopausal osteoporosis","volume":"17","author":"Vasikaran","year":"1995","journal-title":"Bone"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S8756-3282(00)00384-7","article-title":"Effects of alendronate on osteopenic postmenopausal Chinese women","volume":"27","author":"Yen","year":"2000","journal-title":"Bone"},{"issue":"3-4","key":"10.1002\/14651858.CD001155.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/BMR-2005-183-405","article-title":"Comparison of the effects of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis","volume":"18","author":"Yildirim","year":"2005","journal-title":"Journal of Back & Musculoskeletal Rehabilitation"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1002\/14651858.CD001155.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s001980170072","article-title":"An assessment tool for predicting fracture risk in postmenopausal women","volume":"12","author":"Black","year":"2001","journal-title":"Osteoporosis International"},{"issue":"24","key":"10.1002\/14651858.CD001155.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD001155.pub2-BIB0089|cit89","first-page":"S1","article-title":"2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada","volume":"167","author":"Brown","year":"2002","journal-title":"CMAJ"},{"issue":"14","key":"10.1002\/14651858.CD001155.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1996.00440130053006","article-title":"Mortality following fractures in older women. The study of osteoporotic fractures","volume":"156","author":"Browner","year":"1996","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0091|cit91","unstructured":"Coyle D Hadj Tahar A Murphy G Perras C Skidmore B Boucher M Teriparatide and bisphosphonates of treatment of osteoporosis in women: a clinical and economic analysis Canadian Agency for Drugs and Technologies in Health 2006"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0092|cit92","unstructured":"Cates C Visual Rx NNT Calculator 2.0 2004"},{"issue":"7","key":"10.1002\/14651858.CD001155.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporosis International"},{"issue":"9","key":"10.1002\/14651858.CD001155.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a116756","article-title":"Population-based study of survival after osteoporotic fractures","volume":"137","author":"Cooper","year":"1993","journal-title":"American Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD001155.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocrine Reviews"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/archinte.1989.00390110045010","article-title":"Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women","volume":"149","author":"Cummings","year":"1989","journal-title":"Archives of Internal Medicine"},{"issue":"6964","key":"10.1002\/14651858.CD001155.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s001980170152","article-title":"Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women","volume":"12","author":"Doherty","year":"2001","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD001155.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7010","article-title":"How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study","volume":"7","author":"Egger","year":"2003","journal-title":"Health Technology Assessment"},{"issue":"2","key":"10.1002\/14651858.CD001155.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/096228029300200202","article-title":"The statistical basis of meta-analysis","volume":"2","author":"Fleiss","year":"1993","journal-title":"Statistical Methods in Medical Research"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations.","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0102|cit102","first-page":"637","article-title":"Osteoporosis","volume-title":"Therapeutic Choices","author":"Hanley","year":"2003"},{"issue":"14","key":"10.1002\/14651858.CD001155.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0104|cit104","unstructured":"Health Canada Canadian Adverse Drug Reaction Monitoring Program. Alendronate Adverse Reaction Database. Ottawa, 2005"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0105|cit105","unstructured":"Health Canada Medeffect [website] Health Canada 2005"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0106|cit106","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub2-BIB0107|cit107","first-page":"1426","article-title":"Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date","volume":"166","author":"Hodsman","year":"2002","journal-title":"CMAJ"},{"issue":"8","key":"10.1002\/14651858.CD001155.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"Journal of Bone and Mineral Research"},{"issue":"11","key":"10.1002\/14651858.CD001155.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00002018-200225110-00003","article-title":"Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review","volume":"25","author":"Kherani","year":"2002","journal-title":"Drug Safety"},{"issue":"Khosla 2007","key":"10.1002\/14651858.CD001155.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0112|cit112","unstructured":"Alendronate and vertebral fracture risk [multiple letters]. Mayo Clin Proc YR:2005 1233 41"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. [see comment]","volume":"344","author":"McClung","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001155.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/oxfordjournals.aje.a115204","article-title":"Epidemiology of vertebral fractures in women","volume":"129","author":"Melton","year":"1989","journal-title":"American Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD001155.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"Diagnosis","year":"2001","journal-title":"JAMA"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001155.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1007\/BF01623001","article-title":"Preclinical phamacology of alendronate","volume":"3","author":"Rodan","year":"1993","journal-title":"Osteoporosis International"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0895-4356(03)00110-0","article-title":"Should meta-analysts search Embase in addition to Medline?","volume":"56","author":"Sampson","year":"2003","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0118|cit118","unstructured":"Shukla V Treating osteoporosis with teriparatide: many unknowns? [Issues in emerging health technologies issue 51] Canadian Coordinating Office of Health Technology Assessment. 2003"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0119|cit119","volume-title":"Evidence-Based Rheumatology","author":"Tugwell","year":"2004"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0120|cit120","unstructured":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group World Health Organ Tech Rep Ser 1994 1 129"},{"issue":"10","key":"10.1002\/14651858.CD001155.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD001155.pub2-BIB0122|cit122","unstructured":"Wells GA Cranney A Bouchere M Peterson J Shea B Robinson V Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no 69] Ottawa: Canadian Agency for Drugs and Technologies in Health 2006"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001155.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD001155.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T23:16:48Z","timestamp":1708557408000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001155.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":122,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001155.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,23]]}}}